Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer: Final appraisal document

DRAFT guidance recommends atezolizumab with carboplatin and etoposide as an option for untreated extensive-stage small-cell lung cancer in adults, only if they have an ECOG performance status of 0 or 1 and the company provides the drug according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence